OGN GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
OGN
CompareOrganon & Company
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
Organon & Company
Did you know?
Trading 31% above its estimated fair value of $7.77.
Current Price
$11.26
+30.93%GoodMoat Value
$7.77
31.0% overvaluedProfile
Valuation (TTM)
Market Cap$2.93B
P/E15.65
EV$9.65B
P/B3.89
Shares Out259.98M
P/Sales0.47
Revenue$6.22B
EV/EBITDA8.53
Organon & Company (OGN) Quality Analysis
OGN Profitability
Profitability trend analysis coming soon
OGN Growth
Growth trend analysis coming soon
OGN Financial Health
Financial health indicators coming soon
OGN Quality & Fundamental Analysis
Organon & Company (OGN) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. This quality analysis page evaluates Organon & Company's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Organon & Company has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 3.01% and a return on equity (ROE) of 24.87%. Return on assets (ROA) stands at 1.45%.
The debt-to-equity ratio is 11.49, with a current ratio of 1.82. Operating margin is 13.26%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Organon & Company is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.